FDA CGT Approval Rate Expected to Rise
The FDA is expected to approve between 10 and 20 new cell and gene therapies on an annual basis, according to a recent Thermo Fisher Scientific event. This projected increase in approvals is driving the need for robust digital infrastructure within CDMOs. The regulatory bar reinforces the operational imperative for digital batch records, advanced process analytics, and end-to-end traceability.
- In 2024, the FDA approved seven new cell and gene therapy products, matching the number of approvals from the breakthrough year of 2023. These approvals spanned various therapeutic areas, including the first tumor-infiltrating lymphocyte (TIL) therapy for a solid tumor, melanoma, and treatments for rare pediatric diseases. - The global cell and gene therapy CDMO market was valued at approximately $6.31 billion in 2024 and is projected to grow to $74.03 billion by 2034, expanding at a compound annual growth rate (CAGR) of 27.92%. North America held the largest market share in 2024, and the U.S. market alone is expected to reach $28.73 billion by 2034. - A significant challenge in viral vector manufacturing is the purification process, particularly separating empty viral capsids from full, therapeutically active ones. Ion exchange chromatography is a key technology for this separation, which is crucial for increasing treatment efficacy and safety. - To optimize complex manufacturing processes, companies are increasingly developing "digital twins," which are virtual models of a bioprocess. These models use real-time data and simulations to predict the impact of process parameter changes on cell growth and product yield, accelerating development and reducing costly physical experiments. For example, Généthon and Thalès are collaborating on a digital model using AI to optimize bioprocessing yields. - The FDA is actively updating its regulatory framework to keep pace with innovation, releasing draft guidance in May 2024 to streamline drug development and manufacturing. This guidance addresses the complexities of CGT manufacturing, such as limited starting materials and short product shelf-life, and outlines requirements for comparability studies when manufacturing processes change. - Artificial intelligence and machine learning (AI/ML) are being integrated into vector development to design novel AAV capsids with improved cell-targeting specificity. These computational tools can predict which capsid variants will assemble into viable vectors and can optimize for multiple factors like productivity and immune evasion simultaneously. - Electronic Batch Record (EBR) systems are becoming critical for GMP compliance, replacing paper-based records to improve data integrity and traceability. Modern LIMS and EBR platforms offer no-code template configuration and comprehensive audit trails, which are essential for meeting 21 CFR Part 11 and EU Annex 11 standards. - The Alliance for Regenerative Medicine (ARM) noted that in 2024, there were 17 cell and gene therapy programs that could theoretically gain approval. The organization also highlighted the approval of the first adoptive cell therapy for a solid tumor in the U.S. as a key milestone for the year.
